Exhibit 99.1
The following tables present revenues, expenses and profit for each segment for the years ended December 31, 2023 and 2022, and for the three months ended December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023:
United States Segment | ||||||||||||||||||||||||
Year ended December 31, | Three months ended | |||||||||||||||||||||||
2023 | 2022 | December 31, | September 30, | June 30, | March 31, | |||||||||||||||||||
2023 | ||||||||||||||||||||||||
(Unaudited, U.S.$ in millions) | ||||||||||||||||||||||||
Revenues | $ | 7,731 | $ | 7,003 | $ | 2,266 | $ | 1,896 | $ | 1,892 | $ | 1,677 | ||||||||||||
Gross profit | 4,310 | 3,734 | 1,444 | 1,060 | 1,017 | 789 | ||||||||||||||||||
R&D expenses | 604 | 485 | 144 | 156 | 156 | 149 | ||||||||||||||||||
S&M expenses | 938 | 879 | 238 | 243 | 250 | 207 | ||||||||||||||||||
G&A expenses | 378 | 440 | 90 | 93 | 101 | 95 | ||||||||||||||||||
Other income | (5 | ) | (3 | ) | (1 | ) | (2 | ) | (1 | ) | § | |||||||||||||
Segment profit* | $ | 2,394 | $ | 1,934 | $ | 974 | $ | 571 | $ | 511 | $ | 338 |
Europe Segment | ||||||||||||||||||||||||
Year ended December 31, | Three months ended | |||||||||||||||||||||||
2023 | 2022 | December 31, | September 30, | June 30, | March 31, | |||||||||||||||||||
2023 | ||||||||||||||||||||||||
(Unaudited, U.S.$ in millions) | ||||||||||||||||||||||||
Revenues | $ | 4,837 | $ | 4,525 | $ | 1,344 | $ | 1,146 | $ | 1,163 | $ | 1,184 | ||||||||||||
Gross profit | 2,726 | 2,700 | 783 | 648 | 640 | 655 | ||||||||||||||||||
R&D expenses | 220 | 213 | 52 | 62 | 53 | 53 | ||||||||||||||||||
S&M expenses | 767 | 748 | 203 | 184 | 194 | 187 | ||||||||||||||||||
G&A expenses | 263 | 246 | 67 | 66 | 61 | 70 | ||||||||||||||||||
Other income | (2 | ) | (3 | ) | § | § | (1 | ) | § | |||||||||||||||
Segment profit* | $ | 1,478 | $ | 1,496 | $ | 461 | $ | 338 | $ | 334 | $ | 345 |
International Markets Segment | ||||||||||||||||||||||||
Year ended December 31, | Three months ended | |||||||||||||||||||||||
2023 | 2022 | December 31, | September 30, | June 30, | March 31, | |||||||||||||||||||
2023 | ||||||||||||||||||||||||
(Unaudited, U.S.$ in millions) | ||||||||||||||||||||||||
Revenues | $ | 2,351 | $ | 2,352 | $ | 601 | $ | 591 | $ | 578 | $ | 581 | ||||||||||||
Gross profit | 1,160 | 1,224 | 299 | 293 | 283 | 285 | ||||||||||||||||||
R&D expenses | 104 | 119 | 24 | 30 | 23 | 27 | ||||||||||||||||||
S&M expenses | 487 | 467 | 134 | 116 | 125 | 113 | ||||||||||||||||||
G&A expenses | 142 | 154 | 37 | 33 | 34 | 38 | ||||||||||||||||||
Other income | (39 | ) | (54 | ) | (4 | ) | (2 | ) | (31 | ) | (1 | ) | ||||||||||||
Segment profit* | $ | 465 | $ | 538 | $ | 109 | $ | 117 | $ | 132 | $ | 108 |
* | Segment profit is comprised of gross profit for the segment less R&D expenses, S&M expenses, G&A expenses and other income related to the segment. Segment profit does not include amortization and certain other items. |
1
The following tables present revenues by major products and activities for each segment for the years ended December 31, 2023 and 2022 and for the three months ended December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023:
United States Segment | ||||||||||||||||||||||||
Year ended December 31, | Three months ended | |||||||||||||||||||||||
2023 | 2022 | December 31, | September 30, | June 30, | March 31, | |||||||||||||||||||
2023 | ||||||||||||||||||||||||
(Unaudited, U.S.$ in millions) | ||||||||||||||||||||||||
Generic products | 3,138 | 3,155 | 667 | 839 | 884 | 747 | ||||||||||||||||||
AJOVY | 211 | 210 | 57 | 56 | 52 | 46 | ||||||||||||||||||
AUSTEDO | 1,225 | 963 | 408 | 339 | 308 | 170 | ||||||||||||||||||
BENDEKA and TREANDA | 237 | 309 | 52 | 56 | 67 | 62 | ||||||||||||||||||
COPAXONE | 297 | 359 | 72 | 98 | 56 | 71 | ||||||||||||||||||
Anda | 1,577 | 1,471 | 394 | 367 | 392 | 424 | ||||||||||||||||||
Other | 1,047 | 536 | 616 | 142 | 131 | 158 | ||||||||||||||||||
Total | $ | 7,731 | $ | 7,003 | $ | 2,266 | $ | 1,896 | $ | 1,892 | $ | 1,677 |
Europe Segment | ||||||||||||||||||||||||
Year ended December 31, | Three months ended | |||||||||||||||||||||||
2023 | 2022 | December 31, | September 30, | June 30, | March 31, | |||||||||||||||||||
2023 | ||||||||||||||||||||||||
(Unaudited, U.S.$ in millions) | ||||||||||||||||||||||||
Generic products | 3,664 | 3,466 | 938 | 886 | 909 | 932 | ||||||||||||||||||
AJOVY | 160 | 124 | 45 | 41 | 39 | 36 | ||||||||||||||||||
COPAXONE | 231 | 268 | 56 | 55 | 60 | 59 | ||||||||||||||||||
Respiratory products | 265 | 273 | 70 | 61 | 66 | 68 | ||||||||||||||||||
Other | 516 | 393 | 234 | 104 | 89 | 89 | ||||||||||||||||||
Total | $ | 4,837 | $ | 4,525 | $ | 1,344 | $ | 1,146 | $ | 1,163 | $ | 1,184 |
International markets Segment | ||||||||||||||||||||||||
Year ended December 31, | Three months ended | |||||||||||||||||||||||
2023 | 2022 | December 31, | September 30, | June 30, | March 31, | |||||||||||||||||||
2023 | ||||||||||||||||||||||||
(Unaudited, U.S.$ in millions) | ||||||||||||||||||||||||
Generic products | 1,932 | 1,980 | 506 | 470 | 478 | 477 | ||||||||||||||||||
AJOVY | 63 | 42 | 19 | 18 | 14 | 13 | ||||||||||||||||||
COPAXONE | 63 | 64 | 12 | 16 | 17 | 17 | ||||||||||||||||||
Other | 293 | 266 | 64 | 87 | 69 | 74 | ||||||||||||||||||
Total | $ | 2,351 | $ | 2,352 | $ | 601 | $ | 591 | $ | 578 | $ | 581 |
2
The following tables present revenues by major products and activities for Canada for the years ended December 31, 2023 and 2022 and for the three months ended December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023:
Canada | ||||||||||||||||||||||||
Year ended December 31, | Three months ended | |||||||||||||||||||||||
2023 | 2022 | December 31, | September 30, | June 30, | March 31, | |||||||||||||||||||
2023 | ||||||||||||||||||||||||
(Unaudited, U.S.$ in millions) | ||||||||||||||||||||||||
Generic products | 337 | 394 | 86 | 89 | 84 | 77 | ||||||||||||||||||
AJOVY | 20 | 7 | 6 | 6 | 5 | 3 | ||||||||||||||||||
AUSTEDO | — | — | — | — | — | — | ||||||||||||||||||
BENDEKA and TREANDA | 4 | 7 | 1 | 1 | 1 | 1 | ||||||||||||||||||
COPAXONE | 23 | 28 | 5 | 5 | 8 | 5 | ||||||||||||||||||
Anda | — | — | — | — | — | — | ||||||||||||||||||
Other | 9 | 13 | 1 | 4 | 1 | 2 | ||||||||||||||||||
Total | $ | 393 | $ | 449 | $ | 99 | $ | 106 | $ | 99 | $ | 89 |
3